Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. (October 2019)

• Record Type: Journal Article
• Authors: Bousquet, Elodie; Zhao, Min; Daruich, Alejandra; Behar-Cohen, Francine
• Is Part Of: Experimental eye research. Volume 187(2019)
• Publication Date: 2019-10
• Subjects: Central serous chorioretinopathy -- Mineralocorticoid receptor antagonists -- Spironolactone -- Eplerenone; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2019.107754
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: Central serous chorioretinopathy (CSCR) is part of the pachychoroid spectrum disorders, characterized by serous retinal detachments, retinal pigment epithelium alterations and dilation of choroidal vessels. No consensus exists regarding the clinical classification and the physiopathogenic mechanisms of the disease, delaying the comprehension of the most optimal treatment options. An overactivation of the mineralocorticoid receptor (MR) pathway in the choroid/retina has been suggested in CSCR. Since, MR antagonists could target the affected RPE/choroid in CSCR and have shown to act as disease modifier drugs inducing tissue remodeling in other organs (heart, kidney, vessels), we summarize here the pre-clinical and clinical evidence for using oral mineralocorticoid receptor antagonist in the treatment of CSCR. Highlights: Central serous chorioretinopathy is part of the pachychoroid spectrum disorders. No consensus exists regarding the clinical classification of the disease. The physiopathogenic mechanisms and the optimal treatment options remains unclear. The choroid/RPE complex is a mineralocorticoid receptor target. We summarize evidence for using oral mineralocorticoid receptor antagonist treatment.